Abstract
Atrial cardiopathy is a critical driver of embolic stroke and cognitive dysfunction. While Left Atrial Volume indexed to body surface area (LAVi) is the current clinical standard for assessment, it lacks specificity due to its inability to distinguish pathological changes from benign physiological remodeling. This study investigates the Left Atrial to Left Ventricular (LA:LV) volume ratio as a more precise marker of pathological atrial remodeling. Using data from the UK Biobank (n=38,848) and a clinical stroke cohort (n=1,273), we demonstrate that the LA:LV ratio is significantly associated with ischemic stroke risk and cognitive decline, outperforming LAVi in identifying atrial fibrillation as a stroke etiology.
Introduction
The identification of atrial cardiopathy—structural or functional alterations of the left atrium—is paramount in preventing embolic strokes of undetermined source (ESUS). For decades, clinicians have relied on the Left Atrial Volume index (LAVi) to assess risk. However, LAVi is limited by its inability to differentiate between pathological enlargement and the benign physiological remodeling often seen in physically active individuals. In such cases, both the atrium and ventricle enlarge proportionally, which can lead to a high LAVi reading in a perfectly healthy heart.
The Left Atrial to Left Ventricular (LA:LV) volume ratio has emerged as a potential solution. By comparing the size of the atrium relative to the ventricle, this metric specifically targets "unbalanced" remodeling, where atrial growth occurs independently of ventricular changes—a hallmark of disease.
Methodology
This research utilized a two-pronged approach to validate the LA:LV ratio across both general and clinical populations.
1. Population-Based Analysis (UK Biobank)
The researchers analyzed Cardiac Magnetic Resonance (CMR) imaging from the UK Biobank. The cohort included 26,955 participants for stroke risk analysis and 17,133 for cognitive assessment. The LA:LV ratio was calculated by dividing the maximal LA volume at end-systole by the LV end-diastolic volume. Researchers employed cause-specific hazard models for stroke risk and multivariate linear regression for cognitive function.
2. Clinical Validation (USZ Stroke Cohort)
To test the metric's diagnostic utility, the team retrospectively analyzed 1,273 ischemic stroke patients from the University Hospital Zurich (USZ). Using echocardiography data, they compared the ability of LA:LV and LAVi to identify Atrial Fibrillation (AF) as the underlying cause of stroke.
3. Neuroimaging Phenotypes
The study also mapped heart metrics against 66 cortical regions to determine if atrial cardiopathy correlates with specific patterns of brain atrophy.
Key Insights: The "Balance" Factor
The fundamental advantage of the LA:LV ratio lies in its sensitivity to proportionality. In a healthy, athletic heart, the atrium and ventricle grow in tandem, maintaining a stable ratio. In contrast, atrial cardiopathy typically involves atrial dilation without a corresponding increase in ventricular volume. This "spike" in the ratio serves as a specific red flag for pathology that LAVi often misses.
Results
Stroke and TIA Risk
In the UK Biobank population, the LA:LV ratio was a significant predictor of ischemic stroke or transient ischemic attack (TIA), with a Hazard Ratio (HR) of 1.15 (95% CI 1.01-1.30, p = 0.04). Notably, the traditional LAVi metric failed to reach statistical significance in the same model (HR 1.11, p = 0.14), suggesting that the ratio is a more sensitive predictor in the general population.
Cognitive Health and Brain Atrophy
The study found that atrial cardiopathy is not merely a stroke risk but a broader threat to brain health. A higher LA:LV ratio was more strongly associated with worse cognitive function (coefficient -0.024) than LAVi (-0.010). Furthermore, neuroimaging revealed that elevated LA:LV ratios correlate with atrophy in the temporal lobe, insula, and cingulate cortex—areas vital for cognitive processing. This suggests a specific "heart-brain" phenotype where cardiac dysfunction contributes to "silent" neural degradation through micro-emboli or inflammation.
Diagnostic Performance
In the USZ clinical cohort, the LA:LV ratio demonstrated superior diagnostic accuracy in identifying AF as the cause of stroke. The Area Under the Curve (AUC) for the LA:LV ratio was 0.856, significantly higher than the 0.808 achieved by LAVi (p = 0.03).
Discussion and Clinical Implications
The LA:LV ratio offers a more nuanced understanding of atrial health. Its superiority in predicting stroke and cognitive decline stems from its ability to filter out benign physiological changes.
From a clinical perspective, the LA:LV ratio is highly practical. Because both LA and LV volumes are standard measurements in routine echocardiograms and CMR, this metric can be calculated and implemented immediately without the need for new technology or specialized training.
Limitations and Future Work
While promising, the study has limitations. As an observational study, it establishes association rather than direct causality. Additionally, the cohorts were predominantly White, which may limit the generalizability of the findings to more diverse populations. Patients with existing heart failure or reduced ejection fraction were also excluded, necessitating further research in these specific subgroups.
Future prospective multicenter trials are required to establish sex-specific reference values and formally integrate the LA:LV ratio into clinical diagnostic workups for stroke prevention and brain health monitoring.
Conclusion
The LA:LV ratio represents a significant advancement in the detection of atrial cardiopathy. By providing a more accurate marker for stroke risk and cognitive decline, it has the potential to refine clinical diagnostic workups and improve long-term outcomes for patients at risk of heart-brain complications.
Summary updated